First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement Academic Article uri icon

Overview

MeSH Major

  • Kinesin
  • Liver Neoplasms
  • Nanoparticles
  • RNA Interference
  • RNA, Small Interfering
  • Vascular Endothelial Growth Factor A

abstract

  • The fi ndings in this report show safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel fi rst-in-class LNP-formulated RNAi therapeutic in patients with cancer. The ability to harness RNAi to facilitate specifi c multitargeting, as well as increase the number of druggable targets, has important implications for future drug development in oncology.

authors

publication date

  • April 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-12-0429

PubMed ID

  • 23358650

Additional Document Info

start page

  • 406

end page

  • 17

volume

  • 3

number

  • 4